Focused On-demand Library for Alpha-2-macroglobulin receptor-associated protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P30533

UPID:

AMRP_HUMAN

Alternative names:

Low density lipoprotein receptor-related protein-associated protein 1

Alternative UPACC:

P30533; D3DVR9; Q2M310; Q53HQ3; Q53HS6

Background:

Alpha-2-macroglobulin receptor-associated protein, also known as Low density lipoprotein receptor-related protein-associated protein 1, plays a crucial role as a molecular chaperone for LDL receptor-related proteins. It is instrumental in regulating their ligand binding activity along the secretory pathway, ensuring proper cellular function and homeostasis.

Therapeutic significance:

Linked to Myopia 23, autosomal recessive, a condition where vision is better for near objects than for far due to the focus of parallel rays from a distant object in front of the retina, this protein's gene variants are pivotal. Understanding the role of Alpha-2-macroglobulin receptor-associated protein could open doors to potential therapeutic strategies for myopia and related refractive errors.